Edition:
United States

Aurobindo Pharma Ltd (ARBN.NS)

ARBN.NS on National Stock Exchange of India

703.80INR
1:18am EDT
Change (% chg)

Rs-0.95 (-0.13%)
Prev Close
Rs704.75
Open
Rs711.90
Day's High
Rs715.00
Day's Low
Rs701.00
Volume
558,131
Avg. Vol
3,261,818
52-wk High
Rs895.00
52-wk Low
Rs503.05

ARBN.NS

Chart for ARBN.NS

About

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system,... (more)

Overall

Beta: 0.95
Market Cap(Mil.): Rs412,900.59
Shares Outstanding(Mil.): 585.88
Dividend: 1.25
Yield (%): 0.55

Financials

  ARBN.NS Industry Sector
P/E (TTM): 18.43 31.45 32.56
EPS (TTM): 38.23 -- --
ROI: -- 15.33 14.89
ROE: -- 16.35 16.13

BRIEF-Aurobindo Pharma gets USFDA approval for drugs used for treatement of HIV-1 infection

* Receives USFDA tentative approval for Dolutegravir, Lamivudine & Tenofovir Disoproxil Fumarate tablets

Aug 20 2017

UPDATE 1-Aurobindo Pharma Q1 profit drops 11 pct, misses estimates

Aug 9 Indian drugmaker Aurobindo Pharma Ltd reported a 11 percent fall in quarterly profit, hurt by lower sales from its formulations business in the U.S. and pre-launch disruptions of a pan-India tax reform.

Aug 09 2017

BRIEF-India's Aurobindo Pharma June-qtr consol profit down about 11 pct

* June quarter consol net profit 5.19 billion rupees versus 5.85 billion rupees last year

Aug 09 2017

Indian shares close higher; Aurobindo Pharma leads

July 19 Indian shares recovered on Wednesday as cigarette maker ITC rebounded and drugmakers gained on hopes of U.S. regulatory approvals and the launches of new drugs.

Jul 19 2017

Indian shares rise as drugmakers, consumer stocks gain

July 19 Indian shares rose on Wednesday, with drugmaker Aurobindo Pharma Ltd up on hopes of higher U.S. sales and consumer staple Hindustan Unilever hitting a record high after its June-quarter profit beat expectations.

Jul 19 2017

BRIEF-Aurobindo Pharma gets USFDA approval for Sevelamer Carbonate tablets

* Says Aurobindo Pharma receives USFDA approval for Sevelamer Carbonate tablets

Jul 18 2017

BRIEF-Aurobindo Pharma gets USFDA approval for drug for treating chronic kidney disease

* Aurobindo Pharma - receives USFDA approval for Sevelamer Carbonate Oral Suspension

Jun 15 2017

BRIEF-Aurobindo Pharma gets FDA nod for generic ADHD drug

* Says Aurobindo Pharma receives USFDA approval for atomoxetine capsules

May 31 2017

Indian shares edge up to record closes; Aurobindo Pharma surges

May 30 Indian shares rose for a fourth straight session to hit record closing highs, as Aurobindo Pharma jumped after saying it would not be too impacted by price erosion in the U.S. market, and sentiment was boosted by the arrival of monsoon rains.

May 30 2017

BRIEF-Aurobindo Pharma expects U.S. drug price erosion to continue for at least another 4 qtrs - exec

* Exec says expects U.S. drug price erosion to continue for at least another four quarters

May 30 2017

Earnings vs. Estimates